BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, a developer of technology-based solutions for cellular engineering, today announced that it entered into a collaboration agreement with Novartis under which the two companies will utilize Caribou's proprietary CRISPR-Cas9 platform to research new CRISPR-based drug target screening and validation technologies.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
